Sales are small and pre-planned, so no bearish signal. The key catalyst remains the December 17 PDUFA date for relacorilant. Monitor for any insider buying ahead of that event, which would be more informative.
Drug in focus
CORT drug pipeline →Lifyorli
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Lifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.
- Next catalyst
- PDUFA date · Dec 17, 2026 31d
What to watchThe next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.
Price Chart
How similar events traded
Executive Summary
Two insiders at Corcept Therapeutics sold shares in the week following a strong Q3 earnings report. Director Swisher sold 1,500 shares at $74.07 and insider Maduck sold 8,600 shares at $82.02, both under 10b5-1 plans. Total open-market sales of $818K represent about 0.01% of market cap, a trivial amount that does not signal a change in outlook.
Key Financial Metrics
Key Facts
- Two insiders sold shares in the 7 days following Q3 2026 earnings (Nov 3)
- Total open-market sales: $818K (0.01% of $8.2B market cap)
- Both sales were under 10b5-1 plans, indicating pre-planned transactions
- Q3 revenue $340.5M (+64% YoY), EPS $1.01 vs consensus $0.84
- PDUFA for relacorilant in Cushing's syndrome is Dec 17, 2026
Financial Impact
Open-market sales of $818K, trivial relative to $8.2B market cap
Risk Factors
- Insider sales are pre-planned under 10b5-1, not opportunistic
- Total dollar value is immaterial relative to market cap
- No open-market buying to offset the sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1794605485977 |
Track record
36 reports on CORT
8 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Viewing Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers